tbuckley/cabot-search huggingface dataset:
OP0102-PARE NOVEL AND INNOVATIVE APPROACHES TO RAISING AWARENESS OF CHILDHOOD ARTHRITIS
Authors: R. Beesley, R. Beesley
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Community awareness that children and young people (CYP) get arthritis is low[1]. Low awareness is associated with delays in diagnosis, worse clinical outcomes, and adverse societal factors such as stigma and isolation. Raising awareness of childhood arthritis is crucial in combatting these issues to improve the lives of those living with Juvenile Idiopathic Arthritis (JIA). <h3>Objectives:</h3> To develop and implement novel and innovative approaches to raising awareness of childhood arthritis. <h3>Methods:</h3> Juvenile Arthritis Research, a patient organisation in the UK that focusses solely on Juvenile Idiopathic Arthritis (JIA) developed a range of awareness-raising projects with the intention of increasing awareness of childhood arthritis in the general community. These projects have included: Developing physical and online resources – the #ThinkJIA campaign – with support from rheumatologists, clinicians, healthcare professionals, parents and CYP; Supporting initiatives such as WORD Day through intensive social media campaigns; Providing physical resource packs to schools to raise awareness through bookmarks, stickers, badges, leaflets, and presentations; Empowering children and young people to raise awareness in their schools and communities; Converting an empty building into an information hub, with large-scale window films presenting awareness-raising messages; Supporting local community events by providing running tops and T-shirts with awareness-raising messaging; and Local and national media campaigns, based on the above projects. <h3>Results:</h3> The awareness-raising projects have reached many thousands of people across the UK and worldwide (Table 1). Bringing an empty building back into use has generated significant interest from local people, and the large window films (Figure 2) are visible from the major road outside (with over 20,000 vehicles passing each day). <h3>Conclusion:</h3> Raising awareness that CYP get arthritis is a vital step in reducing delays to diagnosis and reducing the burdens of isolation, loneliness and stigma. Innovative approaches are effective and low-cost tools to deliver key messages to the community, supported by high quality and verified clinical-based information. <h3>REFERENCES:</h3> [1] Beesley RP &amp; Beesley RM (2023) Community awareness of childhood arthritis in the UK. In press: Rheumatology Advances In Practice. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1656-PARE THE EFFECT OF THERAPEUTIC PATIENT EDUCATION ON DIETARY PRACTICES AND PHYSICAL ACTIVITY
Authors: N. Tamir, K. Nassar, A. Mghiouach, F. A. Aznag, J. Daoudim, S. Sboul, A. Ajerouassi, S. Zaher, S. Janani
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Osteoporosis is the most common benign debilitating bone disease. Its management requires a demanding medication regimen over several years and lifestyle changes. Patient therapeutic education (PTE) aims to support the patient in their therapeutic approach. <h3>Objectives:</h3> The objective of our study was to evaluate the impact of therapeutic education for osteoporotic patients on diet and physical activity. <h3>Methods:</h3> This prospective study was conducted in the rheumatology department from August 2023 to November 2023, including patients who participated in the PTE program. Data collection was performed using a questionnaire filled out at the end of each PTE session and during the bone follow-up consultation. <h3>Results:</h3> We included 120 patients, with 91.6% women and 8.3% men. The sex ratio was 0.09. The average duration of the disease was 3 years. 73% of patients adjusted their diet through PTE, opting for a balanced diet rich in calcium and vitamins. 14% of patients believed they already had an adapted diet, and 13% reported difficulty adapting their diet. These patients were also being treated for gout or neoplasms of the breast, prostate, or colon. Regarding physical activity, 61% of patients chose walking, 11.6% joined a gym, and the remaining patients mentioned exercises not suitable for their situation. <h3>Conclusion:</h3> PTE plays a major role in the management of osteoporosis patients today, helping them better understand their disease and treatments, and fostering greater adherence to care to maintain or improve their quality of life. In our study, we observed a significant improvement in dietary practices and physical activity after PTE. <h3>REFERENCES:</h3> [1] Caroline Jeansolin. L' éducation thérapeutique du patient appliquée à l'ostéoporose: l'école de l'ostéoporose d'Epinal.: Evaluation méthodologique et première année d'activité. Sciences du Vivant [q-bio]. 2008. ffhal-01733754. Submitted on 14 Mar 2018. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS1063 EXPLORING GENETIC AND IMMUNE CELL DYNAMICS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH EPSTEIN–BARR VIRUS INFECTION VIA COMBINED MICROARRAY AND SINGLE-CELL RNA SEQUENCING ANALYSES
Authors: J. Gui, M. Fang, J. Tu, X. Chen, L. Sun
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Characterized by its clinical diversity and multisystem involvement, Systemic lupus erythematosus (SLE) is a complex autoimmune disease. The development of SLE is determined by a combination of both genetic and environmental factors. It is well documented that Epstein–Barr virus (EBV) infection is closely associated with SLE. However, it remains unclear which genes and immune cells are pivotal in EBV-infected SLE patients. <h3>Objectives:</h3> We aimed to identify overlapping differentially Expressed Genes (DEGs) and immune cell dynamics in both patients with SLE and patients with EBV infection using array data. Subsequently, we aim to further analyze and verify the results of our single-cell sequencing studies. <h3>Methods:</h3> The public microarray data sets of SLE (GSE50772 and GSE81622) or EBV infection (GSE85599 and GSE45918) were obtained from the Gene Expression Omnibus (GEO) database. Subsequently, we conducted differential gene expression analysis to identify overlapping DEGs and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was carried out based on the overlapping DEGs. Subsequently, machine learning approaches were applied to identify key genes from the overlapping DEGs. Finally, we conducted single cell RNA-sequencing in PBMCs isolated from EBV positive SLE patients (SLE-EBV+), EBV negative SLE patients (SLE-EBV-) and normal controls. <h3>Results:</h3> In total, 58 overlapping DEGs were identified, comprising 23 up-regulated genes and 35 down-regulated genes. The most significantly enriched pathways were recognized as oocyte meiosis and circadian rhythm. In addition, we employed machine learning algorithms to select 5 genes (IFI27, TXK, RAPGEF6, PIK3IP1, PSENEN) as key genes (Figure 1). The proportion of T cells CD4 memory resting was significantly decreased in both the SLE database and the EBV infection database. In our scRNA-seq data, the expression of IFI27 was significantly different in all CD4 T cell subsets between SLE-EBV+ and SLE-EBV- patients (Figure 2). Significant differences were observed in the expression of the other four genes (TXK, RAPGEF6, PIK3IP1, PSENEN) in CD8 T cells between SLE-EBV+ and SLE-EBV- patients. TXK, RAPGEF6, and PIK3IP1 also exhibited significant differences in monocytes between SLE-EBV+ patients and EBV- patients. <h3>Conclusion:</h3> The identification of five key genes (IFI27, TXK, RAPGEF6, PIK3IP1, and PSENEN) suggests their potential involvement in the pathogenesis of SLE associated with EBV infection. Notably, IFI27 is considered the most important gene among them. Additionally, our findings suggest that CD4+ T cells, CD8+ T cells, and monocytes may serve as key effector cells playing a vital role in SLE patients infected with the EBV. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0358 SALIVARY GLAND ULTRASOUND FOLLOW-UP IN SJÖGREN’S DISEASE
Authors: K. Perdan-Pirkmajer, S. Praprotnik, Z. Rotar, A. Hocevar
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Salivary gland (SG) ultrasound (US) helps to diagnose and stratify patients with Sjögren's disease (SjD). However, US studies evaluating the course of SG inflammation over time are scarce. <h3>Objectives:</h3> To evaluate the possible progression of US morphological changes of SG in a well-defined SjD patient cohort. <h3>Methods:</h3> One hundred and fifty-one SjD patients diagnosed between January 2016 and December 2018, and fulfilling the ACR/EULAR 2016 classification criteria[1] were invited to participate in a follow- up (FU) US study. Between May and September 2023 patients were invited to a FU visit, at which a detailed clinical and laboratory evaluation was performed, including Schirmer's test, SGUS using Hocevar scoring system[2], calculation of ESSDAI and ESSPRI. For the purpose of the study, an US progression was defined as US score change of &gt;12 points versus baseline. <h3>Results:</h3> Out of 151 patients 82 (54.3%) responded to a FU visit invitation after a median (IQR) follow-up time of 73.1 (63.6, 81.3) months. Patients' baseline characteristics are presented in Table 1. At FU visit 43 (52.4%) and 42 (51.2%) patients reported worsening of ocular and oral sicca symptoms, respectively. Median ESSPRI at FU was 6.0 (4.0; 6.9) and was at least 5 in 53 (64.6%) patients. There were no significant changes in ESR, gamma globulin level and ESSDAI compared to baseline. At FU visit 41 (50%) patients had ESSDAI &gt;0. None of the included patients developed a new lymphoma during FU. At FU visit 41 (50.0%) patients had US changes characteristic for SjD (at baseline 33 (40.2%)). According to the definition, US progression of morphological changes was found in 18 (21.9%)) patients compared to baseline. We found no significant differences in patient age (p=0.516), symptom duration time (p=0.222), oral dryness (p=1.0), glandular swelling (p=0.722), ESR (p=0.423), gamma globulins (p=0.617), ESSDAI (p=0.352), ESSPRI (p=0.384) or immunomodulatory treatment (p=1.0) in patients with and without SGUS progression. <h3>Conclusion:</h3> Over a 6-year period more than one fifth of SjD patients progressed on SG US. However, we found no firm clinical or laboratory predictor of this progression. <h3>REFERENCES:</h3> [1] Shiboski CH, et al. Arthritis Rheumatol 2017;69:35–45. [2] Hočevar A et al. Rheumatology 2005;44(6):768-72. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0019 GOUT AND RISK OF PROSTATE CANCER, A POPULATION BASED STUDY FROM WESTERN SWEDEN
Authors: L. Höper, M. Dehlin, U. Lindström
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Gout, as well as prostate cancer, is common in men and the incidence increases with age. Established risk factors for prostate cancer are age and hereditary factors, while evidence for specific environmental factors are scarce. Increased levels of serum urate is the strongest risk factor for gout development and one cohort study has previously shown an increased risk of prostate cancer development in gout patients. Recent findings from a large multicentre genome-wide association study suggests in situ urate production in the prostate. <h3>Objectives:</h3> To compare the incidence and risk of prostate cancer between male gout patients and general population comparators. <h3>Methods:</h3> This is a population-based and register-based observational cohort study, comparing the incidence and hazard of prostate cancer in patients with gout and matched general population controls. Male gout cases, 18 years or older, were identified by ICD-10 code M10 for gout, between January 1st 2001 through December 31st 2017, in the Western Sweden Healthcare Care Register (VEGA). To each case, up to five controls without any prior diagnosis of gout, were matched for age, sex and place of residence. Relevant comorbidities, medication and urate levels were also retrieved from VEGA. Follow-up started from first diagnosis of gout and ended at first of a diagnosis of prostate cancer, death, migration or study end at December 31st 2017. Cases and controls with a prevalent diagnosis of prostate cancer were excluded. The crude incidence rates (IR) and incidence rate ratio (IRR) were calculated, and comparisons made between the groups. Adjusting for age, time-dependent COX regression was used to analyse the hazard ratio (HR) of prostate cancer in patients with gout compared to population controls. <h3>Results:</h3> We identified 29177 cases of gout with a median age of 67 years and 114 441 matched controls, median age 65 years. The gout cases had an overall higher comorbidity burden at baseline (Table 1). During a median follow-up time of 5 years we identified 960 (3.3%) incident cases of prostate cancer in the gout population compared to 4274 (4.1%) in the controls. The gout population had a significantly lower incidence rate of prostate cancer per 1000 person-years (5.67 95% CI 5.32-6.05) compared to controls (7.01 95% CI 6.81-7.21). Adjusting for age in time-dependent COX regression the relative risk reduction in gout patients for incident prostate cancer was 20% (HR 0.77; 95% CI:0.72-0.83). <h3>Conclusion:</h3> The results in this study show that patients with gout have lower risk of developing prostate cancer than general population comparators. This might imply a protective role of urate in prostate cancer development. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0808 DRUG SURVIVAL IN SPONDYLOARTHRITIS: ANTI-IL17 OUTPERFORMS ANTI-TNF IN FIRST BIOLOGIC TREATMENT
Authors: T. Pham, R. Curmin, B. Flachaire, S. Pinto, F. Tubach, C. Miceli Richard
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> <b>Objectives:</b> Drug survival rates serve as key indicators for assessing both the efficacy and safety of treatments in real life setting. Our aim was to compare the drug retention of first line biologics, anti-tumor necrosis factor (anti-TNF) therapies or anti-interleukin 17 (anti-IL17) therapies. <h3>Methods:</h3> This retrospective cohort study, using data from the French National Health Data System (SNDS), included adult patients diagnosed with Spondyloarthritis (SpA), encompassing axial SpA (axSpA) and Psoriatic Arthritis (PsA), who initiated a first biologic, either anti-TNF or anti-IL17 agent, between January 1, 2015, and December 31, 2018. Follow-up extended until December 31, 2020. The timeframe considered was chosen based on the market release of drugs and to ensure a follow-up of at least 2 years preceding the COVID-19 pandemic period, potential bias on drug survival. Drug survival was described with Kaplan-Meier curves, and predictive factors were identified with a multivariable Cox model adjusted for age, gender, calendar initiation period, and potential indication modifiers such as multiple sclerosis, heart failure, psoriasis, and cancer. <h3>Results:</h3> Of the 26,992 SpA patients initiating a first anti-TNF (n = 26,039) or a first anti-IL17 (n = 953), with a median age at initiation of 44.5 years ± 13.1 and 56.2% female, 25,553 (95.0%) had a diagnosis of axSpA, and 5,453 (20.2%) had PsA. In the entire population, the median drug survival was 13.2 months (CI95 %: 12.8–13.6) for anti-TNF and 18.3 months (CI95 %: 16.2–21.1) for anti-IL17. The retention rates at 1 and 2 years were 52.3% (51.7-53.0) and 37.4% (36.9-38.0) with anti-TNF, compared to 60.6% (57.6-63.8) and 43.6% (40.5-46.9) with anti-IL17. In the axSpA population, the median drug survival was 13.2 months (CI95 %: 12.9–13.7) for anti-TNF and 18.3 months (CI95 %: 19.0–21.5) for anti-IL17 (adjusted HR = 0.83 [0.76-0.91], p &lt;0.001). In the PsA population, the median drug survival was 12.0 months (CI95 %: 11.3–12.5) for anti-TNF and 19.7 months (CI95 %: 16.3–24.5) for anti-IL17 (adjusted HR = 0.73 [0.63-0.83], p &lt;0.001). <h3>Conclusion:</h3> Cohort study of 26,992 patients with SpA initiating a first biologic demonstrated better drug retention with anti-IL17 compared to anti-TNF. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Thao Pham Abbvie, Amgen, Biogen, Celgene, Celltrion, Fresenius-Kabi, Galapagos, Janssen, Lilly, MSD, Nordic, Novartis, Pfizer, Roche-Chugai, Sandoz, Sanofi, UCB, Raphaelle Curmin: None declared, Benoît Flachaire: None declared, Sandrine Pinto: None declared, Florence Tubach: None declared, Corinne Miceli Richard: None declared.
POS1357 DECIPHERING THE CLINICAL QUANDARY: A CROSS-SECTIONAL STUDY ON THE PREVALENCE AND ATTRIBUTES OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS
Authors: H. Elhani, H. Toufik, L. Taoubane, N. El Ouardi, E. A. Houda, E. K. Elmarbouh, H. Zouaki, O. Mkhakh, A. Ould Mohamed, A. Majjad, A. Bezza
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Recently, EULAR (European League Against Rheumatism) has defined Difficult-to-Treat Rheumatoid Arthritis (D2TRA) as a complex condition in patients with Rheumatoid Arthritis (RA). These individuals exhibit a failure to respond to at least two targeted treatments with different mechanisms of action, while displaying signs of disease activity and/or progression. The management of D2TRA proves challenging, both from the perspective of the rheumatologist and the patient. Our study aims to explore the prevalence of this specific entity and characterize its clinical aspects. <h3>Objectives:</h3> By elucidating the multifaceted clinical features and associated factors of D2TRA, our aim is to advance the understanding of this challenging subset within the rheumatoid arthritis spectrum, fostering enhanced strategies for its effective management and therapeutic intervention. <h3>Methods:</h3> We recruited 200 patients with RA (according to the 2010 ACR/EULAR criteria). To analyze factors associated with D2TRA, we divided our population into two groups: a group designated as "D2TRA" and a "control" group. <h3>Results:</h3> In total, 72 (40%) patients met the EULAR definition of D2TRA, with a mean age of 58 ± 10.9 years, compared to 53 ± 9.5 years for the controls. Rituximab was used in 78% of D2TRA patients in our sample. 48.6% received an anti-TNF-alpha, 25% received two anti-TNF alphas, and 15.2% received Tocilizumab. Our results showed that age (OR = 2.24, 95% CI: 1.04–4.02, p = 0.023), disease duration (OR = 2.15, 95% CI: 1.15–3.98, p = 0.05), and BMI (OR = 1.78, 95% CI: 1.09–3.08, p = 0.048) were significantly associated with "D2TRA". Furthermore, patients with intolerance or contraindication to csDMARDs were 1.5 times more likely to develop difficult-to-treat RA (OR = 1.49, 95% CI: 1.02–2.17, p &lt; 0.001). However, no significant associations were observed between "D2TRA" and gender, smoking, or the presence of comorbidities. <h3>Conclusion:</h3> "D2TRA" remains a significant challenge for rheumatologists. The findings of this study emphasize the importance of early management of RA and an individualized therapeutic approach. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1563-HPR VITAMIN D LEVEL IS ASSOCIATED WITH PAIN AND PAIN CATASTROPHIZING IN PATIENTS WITH FIBROMYALGIA SYNDROME
Authors: S. Baglan Yentur, M. Ş. Elbasti
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Low vitamin D levels may increase pain sensitivity, especially by increasing central sensitivity. Fibromyalgia is associated with an imbalance in neurotransmitters and inflammatory pathways in the central nervous system, leading to central sensitization of pain signals. <h3>Objectives:</h3> The aim of this study was to investigate the relationship between Vitamin D level and pain, pain catastrophizing, function, depression and anxiety. <h3>Methods:</h3> A total of 153 patients with FMS and 153 healthy individuals were included in the study. Vitamin D levels were recorded with 5 ml blood samples obtained from patients and healthy individuals. McGill Pain Questionnaire -Short Form (MPQ), Pain Catastrophizing Scale (PCS), Hospital Anxiety and Depression Scale (HADS) and Fibromyalgia Impact Questionnaire (FIQ) were used to evaluate pain, pain catastrophizing, psychological symptoms and function, respectively. Our study received approval from the Ethics Committee at Firat University (2022/14-02) and all patients were informed verbally and in writing about the study and signed a consent form. <h3>Results:</h3> Vitamin D levels were statistically lower in the FMS group (17.71±9.32 ng/ml) compared to the control group (20.40±9.33) (p&lt;0.05). When, no statistical difference was found among classified according to vitamin D subgroups in FIQ, MPQ, PCS and HADS (p&gt;0.05). There was a negative correlation between vitamin D levels and MPQ, all subgroups of PCS (p&gt;0.05), while no significant correlation was found among Vitamin D level and depression, anxiety and function. Our study received approval from the Ethics Committee at Firat University (2022/14-02) and all patients were informed verbally and in writing about the study and signed a consent form. <h3>Conclusion:</h3> It was found that vitamin D levels of patients with FMS were lower than those of healthy individuals and VD levels were associated with pain and pain catastrophizing in this study. VD supplementation may improve pain catastrophizing in patients with FMS. <h3>REFERENCES:</h3> [1] Armstrong DJ, Meenagh GK, Bickle I, Lee ASH, Curran ES, Finch MB. Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clinical rheumatology. 2007;26:551-4. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>